Lucid DiagnosticsLUCD -1.41%26 3-Year ROIIC % is 33.20 as of Dec. 2025. GuruFocus rates LUCD with a GF Score™ of 26/100 and a GF Value™ of $0.81 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 800 Medical Devices & Instruments companies, Lucid Diagnostics ranks better than 78.5% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Lucid Diagnostics's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 33.20%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Lucid Diagnostics's 3-Year ROIIC % or its related term are showing as below:
LUCD's 3-Year ROIIC % is ranked better than 78.5% of 800
companies
in the Medical Devices & Instruments industry
Industry Median: 1.285
vs LUCD: 33.20
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Lucid Diagnostics 3-Year ROIIC % Related Terms
Lucid Diagnostics 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Lucid Diagnostics's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LUCD vs QTRX, INFU, APYX: 3-Year ROIIC % Comparison
For the Medical Devices subindustry, Lucid Diagnostics's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lucid Diagnostics 3-Year ROIIC % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Lucid Diagnostics's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Lucid Diagnostics's 3-Year ROIIC % falls into.
Lucid Diagnostics's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -49.64 (Dec. 2025) - -56.251 (Dec. 2022) )
/
( 29.905 (Dec. 2025) - 9.994 (Dec. 2022) )
=
6.611
/
19.911
=
33.20%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Lucid Diagnostics (LUCD) has a 3-Year ROIIC % of 33.20 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Lucid Diagnostics and its competitors. According to the industry distribution chart, Lucid Diagnostics ranks #172 out of 800 companies in the Medical Devices & Instruments industry, placing it in the top 21.5%.
Is Lucid Diagnostics' 3-Year ROIIC % too high?
Lucid Diagnostics' current 3-Year ROIIC % is 33.20. The Medical Devices & Instruments industry median 3-Year ROIIC % is 1.29. Lucid Diagnostics' value of 33.20 is 2483.7% above this industry median. Based on the distribution chart, Lucid Diagnostics ranks #172 out of 800 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Lucid Diagnostics has a GF Score™ of 26/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lucid Diagnostics' 3-Year ROIIC % compare to QTRX and INFU?
According to the Medical Devices & Instruments industry distribution chart, Lucid Diagnostics ranks #172 out of 800 companies for 3-Year ROIIC %. This places Lucid Diagnostics in the top 22% of its industry — outperforming the majority of peers. The industry median 3-Year ROIIC % is 1.29. Lucid Diagnostics' value of 33.20 is 2483.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Medical Devices & Instruments company?
The median 3-Year ROIIC % among Medical Devices & Instruments companies is 1.29, based on 800 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lucid Diagnostics's current 3-Year ROIIC % of 33.20 is 2483.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Lucid Diagnostics and its competitors. For the Medical Devices & Instruments industry, the median 3-Year ROIIC % is 1.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lucid Diagnostics's current 3-Year ROIIC % is 33.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lucid Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Lucid Diagnostics (LUCD) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.81, compared to a current price of $1.05 — trading 29.6% above its estimated fair value. The current 3-Year ROIIC % is 33.20 and 2483.7% above the Medical Devices & Instruments industry median of 1.29. Lucid Diagnostics' overall GF Score™ is 26/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Lucid Diagnostics (LUCD), the current 3-Year ROIIC % is 33.20 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lucid Diagnostics (LUCD) Overvalued in 2026?
Based on GuruFocus' analysis, Lucid Diagnostics stock appears to be overvalued.
The current stock price of $1.05 is trading 29.6% above its estimated GF Value™ of $0.81.
GuruFocus considers Lucid Diagnostics to be Significantly Overvalued.
Key valuation signals for LUCD:
3-Year ROIIC %: 33.20
GF Value™: $0.81 vs. price of $1.05 (29.6% above fair value)
Industry Position: 2483.7% above the Medical Devices & Instruments median (#172 of 800)
No single metric tells the full story. See the LUCD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
26GF Score
Get the complete analysis for LUCD
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LUCD has been successfully added to your 
